目的系统评价静脉血栓栓塞症(venous thromboembolism,VTE)患者疾病认知和真实体验。方法计算机检索Web of Science、PubMed、CINAHL、Embase、中国知网、万方、维普和中国生物医学文献数据库,检索时间为自建库起至2023年12月止,纳入符...目的系统评价静脉血栓栓塞症(venous thromboembolism,VTE)患者疾病认知和真实体验。方法计算机检索Web of Science、PubMed、CINAHL、Embase、中国知网、万方、维普和中国生物医学文献数据库,检索时间为自建库起至2023年12月止,纳入符合标准的质性研究,使用2016年澳大利亚JBI循证卫生保健中心质性研究质量评价标准对纳入文献进行评价。采用Meta整合的方法对纳入文献进行分析。结果共纳入14篇文献,包括英文文献12篇和中文文献2篇,提炼出55个研究结果,归纳为8个类别,最终确定了3个整合结果:VTE患者对疾病的认知、疾病对VTE患者的影响以及VTE患者的应对策略。结论VTE患者缺乏疾病知识,需加大对该疾病知识宣传的力度,进一步提高基层医疗卫生机构的VTE诊疗水平,降低疾病对患者的影响,加强医患沟通,鼓励共同参与治疗决策,完善VTE防治体系和照护模式。展开更多
Objective: To describe the association between calcific retinal embolism(CRE) and cardiac valve stenosis. Design and setting: Retrospective chart review of patients with clinical criteria for CRE. Patients: 24 patient...Objective: To describe the association between calcific retinal embolism(CRE) and cardiac valve stenosis. Design and setting: Retrospective chart review of patients with clinical criteria for CRE. Patients: 24 patients with CRE who underwent two dimensional echocardiography between 1976 and 1998. Results: Nine patients(38%) had calcific valve stenosis, which was haemodynamically severe in five patients(four aortic and one mitral), four of whom had no cardiac symptoms. Six patients underwent surgical intervention(aortic valve replacement in three patients, mitral and aortic valve replacement in one patient, removal of calcific cardiac pseudotumour in one patient, and carotid endarterectomy in one patient). Conclusions: CRE may be the presenting feature of otherwise asymptomatic, clinically important underlying cardiovascular disease and, in particular, haemodynamically severe calcific valve stenosis.展开更多
BACKGROUND: Selective cyclooxygenase-2 (COX-2) in hibitors have come under s crutiny because of reports su- ggesting an increased cardiovascular risk associated with their use. Experimen tal research suggesting that t...BACKGROUND: Selective cyclooxygenase-2 (COX-2) in hibitors have come under s crutiny because of reports su- ggesting an increased cardiovascular risk associated with their use. Experimen tal research suggesting that these drugs may contribute to a prothrombotic state providessupport for this concern . METHODS: We reviewed all potentially serious cardiovascular events among 2035 patients with a history of colorectal neoplasia who were enrolled in a trial com paring two doses of celecoxib (200 mg or 400 mg twice daily) with placebo for th e prevention of colorectal adenomas. All deaths were categorized as cardiovascul ar or noncardiovascular, and nonfatal cardiovascular events were categorized in a blinded fashion according to a prespecified scheme. RESULTS: For all patients except those who died, 2.8 to 3.1 years of follow-up data were available. A com posite cardiovascular end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure was reached in 7 of 679 patients in the pla cebo group (1.0 percent), as compared with 16 of 685 patients receiving 200 mg o f celecoxib twice daily (2.3 percent; hazard ratio, 2.3; 95 percent confidence i nterval, 0.9 to 5.5) and with 23 of 671 patients receiving 400 mg of celecoxib t wice daily (3.4 percent; hazard ratio, 3.4; 95 percent confidence interval,1.4 t o 7.8). Similar trends were observed for other composite end points. On the basi s of these observations,the data and safety monitoring board recommended early d iscontinuation of the study drug. CONCLUSIONS: Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascula r causes, myocardial infarction, stroke, or heart failure. In light of recent re ports of cardiovascular harm associated with treatment with other agents in this class, these data provide further evidence that the use of COX-2 inhibitors ma y increase the risk of serious cardiovascular events.展开更多
文摘目的系统评价静脉血栓栓塞症(venous thromboembolism,VTE)患者疾病认知和真实体验。方法计算机检索Web of Science、PubMed、CINAHL、Embase、中国知网、万方、维普和中国生物医学文献数据库,检索时间为自建库起至2023年12月止,纳入符合标准的质性研究,使用2016年澳大利亚JBI循证卫生保健中心质性研究质量评价标准对纳入文献进行评价。采用Meta整合的方法对纳入文献进行分析。结果共纳入14篇文献,包括英文文献12篇和中文文献2篇,提炼出55个研究结果,归纳为8个类别,最终确定了3个整合结果:VTE患者对疾病的认知、疾病对VTE患者的影响以及VTE患者的应对策略。结论VTE患者缺乏疾病知识,需加大对该疾病知识宣传的力度,进一步提高基层医疗卫生机构的VTE诊疗水平,降低疾病对患者的影响,加强医患沟通,鼓励共同参与治疗决策,完善VTE防治体系和照护模式。
文摘Objective: To describe the association between calcific retinal embolism(CRE) and cardiac valve stenosis. Design and setting: Retrospective chart review of patients with clinical criteria for CRE. Patients: 24 patients with CRE who underwent two dimensional echocardiography between 1976 and 1998. Results: Nine patients(38%) had calcific valve stenosis, which was haemodynamically severe in five patients(four aortic and one mitral), four of whom had no cardiac symptoms. Six patients underwent surgical intervention(aortic valve replacement in three patients, mitral and aortic valve replacement in one patient, removal of calcific cardiac pseudotumour in one patient, and carotid endarterectomy in one patient). Conclusions: CRE may be the presenting feature of otherwise asymptomatic, clinically important underlying cardiovascular disease and, in particular, haemodynamically severe calcific valve stenosis.
文摘BACKGROUND: Selective cyclooxygenase-2 (COX-2) in hibitors have come under s crutiny because of reports su- ggesting an increased cardiovascular risk associated with their use. Experimen tal research suggesting that these drugs may contribute to a prothrombotic state providessupport for this concern . METHODS: We reviewed all potentially serious cardiovascular events among 2035 patients with a history of colorectal neoplasia who were enrolled in a trial com paring two doses of celecoxib (200 mg or 400 mg twice daily) with placebo for th e prevention of colorectal adenomas. All deaths were categorized as cardiovascul ar or noncardiovascular, and nonfatal cardiovascular events were categorized in a blinded fashion according to a prespecified scheme. RESULTS: For all patients except those who died, 2.8 to 3.1 years of follow-up data were available. A com posite cardiovascular end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure was reached in 7 of 679 patients in the pla cebo group (1.0 percent), as compared with 16 of 685 patients receiving 200 mg o f celecoxib twice daily (2.3 percent; hazard ratio, 2.3; 95 percent confidence i nterval, 0.9 to 5.5) and with 23 of 671 patients receiving 400 mg of celecoxib t wice daily (3.4 percent; hazard ratio, 3.4; 95 percent confidence interval,1.4 t o 7.8). Similar trends were observed for other composite end points. On the basi s of these observations,the data and safety monitoring board recommended early d iscontinuation of the study drug. CONCLUSIONS: Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascula r causes, myocardial infarction, stroke, or heart failure. In light of recent re ports of cardiovascular harm associated with treatment with other agents in this class, these data provide further evidence that the use of COX-2 inhibitors ma y increase the risk of serious cardiovascular events.
